Splice variants of zinc finger protein 695 mRNA associated to ovarian cancer

Journal of Ovarian Research

José Moreno⁷  Guelaguetza Vázquez-Ortiz⁴  Víctor Edén Montes de Oca-Fuentes⁵  Minerva Lazos-Ochoa⁶  Edgar Román-Basaure²  Ricardo López-Romero³  Mauricio Salcedo³  Oscar Alberto Pérez-González¹  Vanessa Villegas-Ruíz³  Alejandro Zentella-Dehesa⁵  Sergio Juárez-Méndez¹ 

[1] Experimental Oncology Laboratory, Research Department, National Institute of Pediatrics, Mexico, D. F, Mexico;Department of Oncology, General Hospital of México O. D, Mexico, D. F, Mexico;Genomic Oncology Laboratory, Medical Research Unit in Oncologic Diseases, Oncology Hospital, National Medical Center Siglo XXI, IMSS, Mexico City, Mexico;Mammalian Genetics Section, NIDDK, National Institutes of Health, 10/9 N104, 10 Center Drive, Bethesda, MD 20892, USA;Unit of Biochemistry, National Institute of Medical Sciences and Nutrition “Salvador Zubirán”, Mexico City, Mexico;Faculty of Medicine, UNAM, General Hospital of México O. D, Mexico, D. F, Mexico;Mexican Faculty of Medicine, Universidad La Salle, Mexico City, Mexico

关键词: ZNF695;    Alternative mRNA splicing;    Ovarian cancer;   

Others  :  805825
DOI  :  10.1186/1757-2215-6-61

 received in 2013-05-28, accepted in 2013-08-24,  发布年份 2013

【 摘 要 】

Background

Studies of alternative mRNA splicing (AS) in health and disease have yet to yield the complete picture of protein diversity and its role in physiology and pathology. Some forms of cancer appear to be associated to certain alternative mRNA splice variants, but their role in the cancer development and outcome is unclear.

Methods

We examined AS profiles by means of whole genome exon expression microarrays (Affymetrix GeneChip 1.0) in ovarian tumors and ovarian cancer-derived cell lines, compared to healthy ovarian tissue. Alternatively spliced genes expressed predominantly in ovarian tumors and cell lines were confirmed by RT-PCR.

Results

Among several significantly overexpressed AS genes in malignant ovarian tumors and ovarian cancer cell lines, the most significant one was that of the zinc finger protein ZNF695, with two previously unknown mRNA splice variants identified in ovarian tumors and cell lines. The identity of ZNF695 AS variants was confirmed by cloning and sequencing of the amplicons obtained from ovarian cancer tissue and cell lines.

Conclusions

Alternative ZNF695 mRNA splicing could be a marker of ovarian cancer with possible implications on its pathogenesis.

【 授权许可】

   
2013 Juárez-Méndez et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Bast RC Jr, Hennessy B, Mills GB: The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009, 9:415-428.
• [2]Scully RE: Classification of human ovarian tumors. Env Health Perspect 1987, 73:15-25.
• [3]Lancaster JM, Dressman HK, Clarke JP, Sayer RA, Martino MA, Cragun JM, Henriott AH, Gray J, Sutphen R, Elahi A, et al.: Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer 2006, 16:1733-1745.
• [4]Maxwell GL, Chandramouli GV, Dainty L, Litzi TJ, Berchuck A, Barrett JC, Risinger JI: Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. Clin Cancer Res 2005, 11:4056-4066.
• [5]Tinker AV, Boussioutas A, Bowtell DD: The challenges of gene expression microarrays for the study of human cancer. Cancer Cell 2006, 9:333-339.
• [6]Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ: Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005, 11:6422-6430.
• [7]Keita M, Bachvarova M, Morin C, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Trinh XB, Bachvarov D: The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle 2013, 12:972-986.
• [8]Treeck O, Schuler S, Haring J, Skrzypczak M, Lattrich C, Ortmann O: icb-1 Gene counteracts growth of ovarian cancer cell lines. Cancer Lett 2013, 335:441-446.
• [9]Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, et al.: Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921.
• [10]Modrek B, Resch A, Grasso C, Lee C: Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res 2001, 29:2850-2859.
• [11]Graveley BR: Alternative splicing: increasing diversity in the proteomic world. Trends Genet 2001, 17:100-107.
• [12]Carninci P: Constructing the landscape of the mammalian transcriptome. J Exp Biol 2007, 210:1497-1506.
• [13]Schmucker D, Clemens JC, Shu H, Worby CA, Xiao J, Muda M, Dixon JE, Zipursky SL: Drosophila Dscam is an axon guidance receptor exhibiting extraordinary molecular diversity. Cell 2000, 101:671-684.
• [14]Venables JP: Unbalanced alternative splicing and its significance in cancer. Bioessays 2006, 28:378-386.
• [15]Hayes GM, Carrigan PE, Miller LJ: Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res 2007, 67:2072-2080.
• [16]Akgul C, Moulding DA, Edwards SW: Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol Life Sci 2004, 61:2189-2199.
• [17]Chen LL, Sabripour M, Wu EF, Prieto VG, Fuller GN, Frazier ML: A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors. Oncogene 2005, 24:4271-4280.
• [18]Wang XQ, Luk JM, Leung PP, Wong BW, Stanbridge EJ, Fan ST: Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma. Clin Cancer Res 2005, 11:483-489.
• [19]Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, Katz A, Isaacs WB, Hebbring S, Komiya A, et al.: A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 2005, 65:1213-1222.
• [20]Thorsen K, Sorensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AM, Kruhoffer M, Laurberg S, Borre M, Wang K, et al.: Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics 2008, 7:1214-1224.
• [21]Adamia S, Reiman T, Crainie M, Mant MJ, Belch AR, Pilarski LM: Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma. Blood 2005, 105:4836-4844.
• [22]Mazoyer S, Puget N, Perrin-Vidoz L, Lynch HT, Serova-Sinilnikova OM, Lenoir GM: A BRCA1 nonsense mutation causes exon skipping. Am J Hum Genet 1998, 62:713-715.
• [23]Singh A, Karnoub AE, Palmby TR, Lengyel E, Sondek J, Der CJ: Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene 2004, 23:9369-9380.
• [24]Zhou YQ, He C, Chen YQ, Wang D, Wang MH: Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene 2003, 22:186-197.
• [25]Bauer TW, Fan F, Liu W, Johnson M, Parikh NU, Parry GC, Callahan J, Mazar AP, Gallick GE, Ellis LM: Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann Surg 2005, 241:748-756. discussion 756–748
• [26]Brembeck FH, Rosario M, Birchmeier W: Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006, 16:51-59.
• [27]Cheng C, Sharp PA: Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol Cell Biol 2006, 26:362-370.
• [28]Wong MP, Cheung N, Yuen ST, Leung SY, Chung LP: Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression. Int J Cancer 1999, 81:845-850.
• [29]Hofstetter G, Berger A, Fiegl H, Slade N, Zoric A, Holzer B, Schuster E, Mobus VJ, Reimer D, Daxenbichler G, et al.: Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene 2010, 29:1997-2004.
• [30]Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF: Characterization of a human ovarian carcinoma cell line (NIH: OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983, 43:5379-5389.
• [31]Fogh J, Wright WC, Loveless JD: Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 1977, 58:209-214.
• [32]Provencher DM, Lounis H, Champoux L, Tetrault M, Manderson EN, Wang JC, Eydoux P, Savoie R, Tonin PN, Mes-Masson AM: Characterization of four novel epithelial ovarian cancer cell lines. In vitro Cell Dev Biol Anim 2000, 36:357-361.
• [33]Hoskins WJ: Prospective on ovarian cancer: why prevent? J Cell Biochem Suppl 1995, 23:189-199.
• [34]Nguyen HN, Averette HE, Hoskins W, Sevin BU, Penalver M, Steren A: National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer 1993, 72:3007-3011.
• [35]Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L, Durand M, Couture S, Froehlich U, Lapointe E, et al.: Cancer-associated regulation of alternative splicing. Nat Struct Mol Biol 2009, 16:670-676.
• [36]Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, Baralle FE: Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987, 6:2337-2342.
• [37]Missler M, Sudhof TC: Neurexins: three genes and 1001 products. Trends Genet 1998, 14:20-26.
• [38]Joseph R, Dou D, Tsang W: Neuronatin mRNA: alternatively spliced forms of a novel brain-specific mammalian developmental gene. Brain Res 1995, 690:92-98.
• [39]Chen CD, Kobayashi R, Helfman DM: Binding of hnRNP H to an exonic splicing silencer is involved in the regulation of alternative splicing of the rat beta-tropomyosin gene. Genes Dev 1999, 13:593-606.
• [40]Merdzhanova G, Gout S, Keramidas M, Edmond V, Coll JL, Brambilla C, Brambilla E, Gazzeri S, Eymin B: The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. Oncogene 2010, 29:5392-5403.
• [41]Guo M, Liu W, Serra S, Asa SL, Ezzat S: FGFR2 isoforms support epithelial-stromal interactions in thyroid cancer progression. Cancer Res 2012, 72:2017-2027.
• [42]Dery KJ, Gusti V, Gaur S, Shively JE, Yen Y, Gaur RK: Alternative splicing as a therapeutic target for human diseases. Methods Mol Biol 2009, 555:127-144.
• [43]Krishna SS, Majumdar I, Grishin NV: Structural classification of zinc fingers: survey and summary. Nucleic Acids Res 2003, 31:532-550.
• [44]Friedman JR, Fredericks WJ, Jensen DE, Speicher DW, Huang XP, Neilson EG, Rauscher FJ 3rd: KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes Dev 1996, 10:2067-2078.
• [45]Vissing H, Meyer WK, Aagaard L, Tommerup N, Thiesen HJ: Repression of transcriptional activity by heterologous KRAB domains present in zinc finger proteins. FEBS Lett 1995, 369:153-157.
• [46]Pengue G, Calabro V, Bartoli PC, Pagliuca A, Lania L: Repression of transcriptional activity at a distance by the evolutionarily conserved KRAB domain present in a subfamily of zinc finger proteins. Nucleic Acids Res 1994, 22:2908-2914.
• [47]Agata Y, Matsuda E, Shimizu A: Two novel Kruppel-associated box-containing zinc-finger proteins, KRAZ1 and KRAZ2, repress transcription through functional interaction with the corepressor KAP-1 (TIF1beta/KRIP-1). J Biol Chem 1999, 274:16412-16422.